Triventures
ActiveOverview
Triventures is a global early-stage venture capital firm founded in 2010 that invests in companies at the convergence of healthcare and technology. The firm manages approximately $200 million in assets and focuses on data-driven healthcare solutions, medical devices, fintech, cybersecurity, and e-commerce, with a particular emphasis on companies led by exceptional entrepreneurs. Triventures operates with offices in Israel, Silicon Valley, and Canada, and has established itself as a significant player in the venture ecosystem through strategic partnerships and a robust portfolio of over 50 successful exits.
History
Triventures was founded in 2010 and initially focused on medical devices, becoming the first Israeli venture capital firm to recognize the potential of data-driven solutions and digital health investments. The firm later expanded its investment thesis to encompass the broader convergence of health and technology, including fintech, cybersecurity, and e-commerce. Led by co-founders Michal Geva and Dr. Peter Fitzgerald, the team has guided over 30 companies to successful exits and reviews approximately 700 companies annually. Notable portfolio exits include acquisitions by major corporations such as Stryker, Palo Alto Networks, and TransEnterix, demonstrating the firm's ability to identify high-potential ventures.
Product Lines
| Product Line | Positioning | Price Range |
|---|---|---|
| Early-stage venture capital investments | Pre-seed and seed stage funding for health-tech convergence companies | $500K - $10M+ |
| Series A and Series B+ funding | Growth-stage capital for validated business models | $1M - $98M |
| Strategic advisory and partnership services | Operator-first support leveraging healthcare and entrepreneurship expertise | Included with investment |
Manufacturing
As a venture capital firm, Triventures does not manufacture physical products. Instead, the firm provides capital and strategic guidance to portfolio companies across various sectors. The firm leverages partnerships with healthcare institutions, including collaboration with Sheba Medical Center for access to significant health data assets, and maintains a global network spanning the United States, Israel, and Canada to support portfolio company growth.
Notable Products
- Ginkgo Bioworks investment - Pioneering work in synthetic biology and genomics
- Atomwise investment - Advanced diagnostics and AI-driven drug discovery
- Verge Genomics investment - Genomics-focused breakthroughs in healthcare innovation
Reputation
Triventures is recognized within the venture capital community as a specialized investor with deep expertise in healthcare innovation and data-driven solutions. The firm is noted for its operator-first mindset and strong track record of identifying cross-industry breakthroughs that converge health and technology sectors. Its strategic partnerships with medical institutions and established network across multiple geographies enhance its credibility, though as a specialized healthcare-focused fund, its investment thesis may limit its appeal to entrepreneurs outside the health-tech convergence space.